CG Oncology (NASDAQ:CGON) Shares Gap Up After Insider Buying Activity

CG Oncology, Inc. (NASDAQ:CGON) shares gapped up before the market opened on Monday after an insider bought additional shares in the company. The stock had previously closed at $33.34, but opened at $35.10. CG Oncology shares last traded at $34.33, with a volume of 114,584 shares.

Specifically, Director Brian Guan-Chyun Liu bought 1,515,151 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were bought at an average price of $33.00 per share, with a total value of $49,999,983.00. Following the purchase, the director owned 1,515,151 shares of the company’s stock, valued at $49,999,983. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Wall Street Analyst Weigh In

Several research firms have weighed in on CGON. Royal Bank Of Canada cut their price target on CG Oncology from $68.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, July 16th. Piper Sandler began coverage on CG Oncology in a report on Monday, August 18th. They set an “overweight” rating and a $55.00 price target for the company. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Zacks Research upgraded CG Oncology from a “strong sell” rating to a “hold” rating in a report on Monday, September 1st. Finally, The Goldman Sachs Group upgraded CG Oncology to a “strong-buy” rating and set a $40.00 price target for the company in a report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.91.

CG Oncology Trading Up 2.3%

The stock has a market capitalization of $2.60 billion, a PE ratio of -19.26 and a beta of 0.87. The firm’s 50-day simple moving average is $27.20 and its two-hundred day simple moving average is $25.55.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. As a group, research analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Institutional Investors Weigh In On CG Oncology

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of CG Oncology during the 4th quarter valued at $41,000. Winthrop Capital Management LLC bought a new position in CG Oncology in the 2nd quarter worth $38,000. CWM LLC increased its holdings in shares of CG Oncology by 3,957.7% during the 1st quarter. CWM LLC now owns 2,110 shares of the company’s stock worth $52,000 after purchasing an additional 2,058 shares during the period. GAMMA Investing LLC increased its holdings in shares of CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company’s stock worth $56,000 after purchasing an additional 2,102 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock worth $77,000 after purchasing an additional 398 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.